AIKIDO PHARMA INC (AIKI) Stock Price & Overview
NASDAQ:AIKI • US0088753043
Current stock price
The current stock price of AIKI is 3.56 USD. Today AIKI is up by 0.28%. In the past month the price decreased by -10.1%. In the past year, price decreased by -67.28%.
AIKI Key Statistics
- Market Cap
- 19.527M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.37
- Dividend Yield
- N/A
AIKI Stock Performance
AIKI Stock Chart
AIKI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to AIKI. When comparing the yearly performance of all stocks, AIKI is a bad performer in the overall market: 91.78% of all stocks are doing better.
AIKI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AIKI. The financial health of AIKI is average, but there are quite some concerns on its profitability.
AIKI Earnings
AIKI Forecast & Estimates
7 analysts have analysed AIKI and the average price target is 16.32 USD. This implies a price increase of 358.43% is expected in the next year compared to the current price of 3.56.
AIKI Groups
Sector & Classification
AIKI Financial Highlights
Over the last trailing twelve months AIKI reported a non-GAAP Earnings per Share(EPS) of -3.37. The EPS decreased by -879.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AIKI Ownership
AIKI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.18 | 371.899B | ||
| AMGN | AMGEN INC | 15.37 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.1 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.62 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AIKI
Company Profile
AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The Company’s pipeline consists of patented technology from universities and researchers. The firm advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.
Company Info
IPO: 1980-03-18
AIKIDO PHARMA INC
One Rockefeller Plaza, 11Th Floor
New York City NEW YORK 10020 US
CEO: Anthony Hayes
Employees: 4
Phone: 13473217646.0
AIKIDO PHARMA INC / AIKI FAQ
What does AIKI do?
AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The Company’s pipeline consists of patented technology from universities and researchers. The firm advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.
Can you provide the latest stock price for AIKIDO PHARMA INC?
The current stock price of AIKI is 3.56 USD. The price increased by 0.28% in the last trading session.
Does AIKI stock pay dividends?
AIKI does not pay a dividend.
What is the ChartMill technical and fundamental rating of AIKI stock?
AIKI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for AIKIDO PHARMA INC?
AIKIDO PHARMA INC (AIKI) has a market capitalization of 19.53M USD. This makes AIKI a Nano Cap stock.
Can you provide the upcoming earnings date for AIKIDO PHARMA INC?
AIKIDO PHARMA INC (AIKI) will report earnings on 2023-03-27.
What is the ownership structure of AIKIDO PHARMA INC (AIKI)?
You can find the ownership structure of AIKIDO PHARMA INC (AIKI) on the Ownership tab.